AN2 Therapeutics (ANTX)
(Delayed Data from NSDQ)
$1.08 USD
0.00 (0.00%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $1.10 +0.02 (1.85%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ANTX 1.08 0.00(0.00%)
Will ANTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ANTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANTX
AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why
ANTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ANTX
ANTX: AN2 Therapeutics Partners on Chagas Disease Oral Treatment | ANTX Stock News
AN2 Therapeutics, DNDi collaborate on development of AN2-502998
AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to ...
AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute ...
AN2 Therapeutics completes 200-patient observational study in acute melioidosis